Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Virol. 2010 Dec 15. [Epub ahead of print] Targeting Hepatitis B virus infected cells with a T-cell receptor like antibody. Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javaid A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A. Viral Hepatitis Laboratory, Infection & Immunity Program, Singapore Institute for Clinical Sciences, A*STAR, Singapore; Immunology Program and Department of Microbiology, National University of Singapore, Singapore; Institute of Cell and Molecular Science, Barts and The London School of Medicine, London, UK; Unit of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy; Roche Pharma research and Early development: Translational Medicine -Virology, Palo Alto, USA; Emerging Viral Diseases, Duke-NUS Graduate Medical School, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Abstract Virus-specific CD8 T cells are activated when their T cell receptors (TCR) recognize the specific viral-peptide MHC-class I complexes (pMHC) present on the surface of infected cells. Antibodies able to recognize the specific pMHC can mimic TCR specificity and represent both a valuable biological tool to visualize pMHC complexes on infected cells and serve as a delivery system for highly targeted therapies. To evaluate these possibilities we created a monoclonal antibody able to specifically recognize a hepatitis B virus (HBV) envelope epitope (Env 183-91) presented by HLA-A201 molecule and we tested its ability to recognize HBV infected hepatocytes and to deliver a cargo to specific target. We demonstrate that this antibody detects and visualizes the processed product of HBV proteins produced in naturally HBV infected cells, is not inhibited by soluble HBV proteins present in patients sera and mediates intracellular delivery of a fluorescent molecule to target cells. Additionally, when compared to CD8 T cells specific for the same HBV epitope, the TCR-like antibody has both a superior sensitivity and a specificity focused on distinct amino acid within the epitope. These data demonstrate that a T cell receptor-like antibody can be used to determine the quantitative relation between HBV replication and specific Ag presentation to CD8 T cells and serve as a novel therapeutic delivery platform for personalized health care of HBV infected patients. PMID: 21159876 [PubMed - as supplied by publisher] Quote
Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Virol. 2010 Dec 15. [Epub ahead of print] Targeting Hepatitis B virus infected cells with a T-cell receptor like antibody. Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javaid A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A. Viral Hepatitis Laboratory, Infection & Immunity Program, Singapore Institute for Clinical Sciences, A*STAR, Singapore; Immunology Program and Department of Microbiology, National University of Singapore, Singapore; Institute of Cell and Molecular Science, Barts and The London School of Medicine, London, UK; Unit of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy; Roche Pharma research and Early development: Translational Medicine -Virology, Palo Alto, USA; Emerging Viral Diseases, Duke-NUS Graduate Medical School, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Abstract Virus-specific CD8 T cells are activated when their T cell receptors (TCR) recognize the specific viral-peptide MHC-class I complexes (pMHC) present on the surface of infected cells. Antibodies able to recognize the specific pMHC can mimic TCR specificity and represent both a valuable biological tool to visualize pMHC complexes on infected cells and serve as a delivery system for highly targeted therapies. To evaluate these possibilities we created a monoclonal antibody able to specifically recognize a hepatitis B virus (HBV) envelope epitope (Env 183-91) presented by HLA-A201 molecule and we tested its ability to recognize HBV infected hepatocytes and to deliver a cargo to specific target. We demonstrate that this antibody detects and visualizes the processed product of HBV proteins produced in naturally HBV infected cells, is not inhibited by soluble HBV proteins present in patients sera and mediates intracellular delivery of a fluorescent molecule to target cells. Additionally, when compared to CD8 T cells specific for the same HBV epitope, the TCR-like antibody has both a superior sensitivity and a specificity focused on distinct amino acid within the epitope. These data demonstrate that a T cell receptor-like antibody can be used to determine the quantitative relation between HBV replication and specific Ag presentation to CD8 T cells and serve as a novel therapeutic delivery platform for personalized health care of HBV infected patients. PMID: 21159876 [PubMed - as supplied by publisher] Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.